For diabetic kidney disease, OPCs can attenuate hyperglycemia-induced adverse cellular factors, such as cellular inflammation, and reduces genetic abnormalities caused by hyperglycemia, for example, caveolin-1 [140]. Here, CAV1 is linked to Hyperglycemia.